Likewise, Honda et al25 assessed the performance for the combination of CA19‐9 and ApoA2 isoform in plasma samples from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort collected up to 18 months prior to PDAC diagnosis, obtaining AUC of 0.75, with SN 43% at SP 98%.25 This evidence concerns the gene APOA2 and cancer.